Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.52 |
| ▸ | BCHE | P06276 | 3/20 | 0.52 |
| ▸ | MAOA | P21397 | 8/20 | 0.52 |
| ▸ | MAOB | P27338 | 8/20 | 0.52 |
| ▸ | BACE1 | P56817 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | PYCR1 | P32322 | 2/20 | 0.32 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL611971 | 0.72 | ACHE (0.53) | ACHEBCHEMAOAMAOBBACE1 | |
| SCHEMBL611410 | 0.72 | ACHE (0.53) | ACHEBCHEMAOAMAOBBACE1 | |
| SCHEMBL611600 | 0.71 | ACHE (0.52) | ACHEBCHEMAOAMAOBBACE1 | |
| SCHEMBL611602 | 0.71 | ACHE (0.52) | ACHEBCHEMAOAMAOBBACE1 | |
| SCHEMBL10053435 | 0.70 | ACHE (0.65) | ACHEBCHEMAOAMAOBBACE1 | |
| SCHEMBL608274 | 0.70 | ACHE (0.65) | ACHEBCHEMAOAMAOBBACE1 | |
| SCHEMBL608273 | 0.70 | ACHE (0.65) | ACHEBCHEMAOAMAOBBACE1 | |
| SCHEMBL112398 | 0.70 | MAOA (1.00) | ACHEBCHEMAOAMAOBBACE1 | |
| SCHEMBL608520 | 0.69 | ACHE (1.00) | ACHEBCHEMAOAMAOBBACE1 | |
| Hydrochloric Acid SCHEMBL30019972 | 0.69 | MAOA (0.97) | ACHEBCHEMAOAMAOBBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802675-B2 | Neuroprotective multifunctional compounds and pharmaceutical compositions comprising them | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD (IL) | 2014-08-12 | — | — | US | disclosed |
| US-20120040993-A1 | NEUROPROTECTIVE MULTIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040993-A1 | NEUROPROTECTIVE MULTIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | GSR, GRIN1, GRIN2A | ACHE 81/4885BCHE 142/4885MAOA 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.